~~<i id='A18536268A'><strike id='A18536268A'><tt id='A18536268A'><pre id='A18536268A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

leisure time

author：knowledge 2025-08-04 06:02:17 - browse：3

An illustration of red blood cells — Adobe

As a boy growing up with hemophilia A, Noah Frederick reserved the end of his annual checkups to talk about new technologies. His doctor walked through various experimental approaches for the bleeding disorder and, invariably, gene therapy. It was coming, he always said, in your lifetime.

Last year, it finally arrived. But Frederick, now a 23-year-old software engineer, isn’t sure he’ll get it. He wants to be part of the sci-fi future gene therapy has always represented, but a recent doctor’s visit left him uncertain.

“I’m on the fence,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

hotspot

explore

focus

Wikipedia

entertainment

hotspot

MollyFerguson/STATTheFoodandDrugAdministrationshouldhaltCassavaSciences’ongoingclinicaltrialsinAlzhe

WSS

Histogen: Failed biotech offers rare public look inside

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Chemotherapy drug shortage eases slightly but still widespread

Senate panel eyes new effort on drug shortages

Roche drug slashes death risk in early

Bristol 'take

explore

leisure time

hotspot

Continuity nursing helped my family in our darkest PICU moments

STAT Summit: The economic case for universal basic health care

Dobbs anniversary: the lost opportunity of abortion as health care

Cassava Sciences’ Alzheimer’s clinical trials should be halted

After affirmative action ruling, medical educators look to 'holistic review'

STAT Readout: Friday, Oct. 20 biotech updates

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

How AI can help patients find reliable information about doctors

Peter Hotez and the public health issue of online harassment

The problems with dementia villages

explore

Chan Zuckerberg Biohub Chicago to focus on inflammation

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Roivant's CEO is a star, but biotech's black hole persists

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Was Amgen transparent enough on FDA's concern on cancer drug?

Roche drug slashes death risk in early

focus

Wikipedia

entertainment

hotspot